Full efficacy and long-term immunogenicity induced by the SARS-CoV-2 vaccine candidate MVA-CoV2-S in mice

[1]  B. Bošnjak,et al.  Immunogenicity and efficacy of the COVID-19 candidate vector vaccine MVA-SARS-2-S in preclinical vaccination , 2021, Proceedings of the National Academy of Sciences.

[2]  M. Davenport,et al.  Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection , 2021, Nature Medicine.

[3]  J. Mascola,et al.  Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19 , 2021, The New England journal of medicine.

[4]  H. Schuitemaker,et al.  Ad26.COV2.S protects Syrian hamsters against G614 spike variant SARS-CoV-2 and does not enhance respiratory disease , 2021, NPJ vaccines.

[5]  P. Earl,et al.  One or two injections of MVA-vectored vaccine shields hACE2 transgenic mice from SARS-CoV-2 upper and lower respiratory tract infection , 2021, Proceedings of the National Academy of Sciences.

[6]  A. Nicholson,et al.  Comparison of rhesus and cynomolgus macaques as an infection model for COVID-19 , 2021, Nature Communications.

[7]  Vineet D. Menachery,et al.  A modified vaccinia Ankara vector-based vaccine protects macaques from SARS-CoV-2 infection, immune pathology, and dysfunction in the lungs , 2021, Immunity.

[8]  Robert J. Fischer,et al.  K18-hACE2 mice develop respiratory disease resembling severe COVID-19. , 2021, PLoS pathogens.

[9]  C. del Fresno,et al.  COVID-19 Vaccine Candidates Based on Modified Vaccinia Virus Ankara Expressing the SARS-CoV-2 Spike Protein Induce Robust T- and B-Cell Immune Responses and Full Efficacy in Mice , 2021, Journal of Virology.

[10]  F. Cosset,et al.  A longitudinal study of SARS-CoV-2-infected patients reveals a high correlation between neutralizing antibodies and COVID-19 severity , 2021, Cellular & Molecular Immunology.

[11]  J. Mascola,et al.  Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine , 2020, The New England journal of medicine.

[12]  S. Jameson,et al.  T Cell Memory: Understanding COVID-19 , 2020, Immunity.

[13]  P. Dormitzer,et al.  Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine , 2020, The New England journal of medicine.

[14]  G. Koh.  Faculty Opinions recommendation of Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK , 2020, Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature.

[15]  Nguyen H. Tran,et al.  Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK , 2020, Lancet.

[16]  Xiwei Wu,et al.  Development of a multi-antigenic SARS-CoV-2 vaccine candidate using a synthetic poxvirus platform , 2020, Nature Communications.

[17]  S. Perlman,et al.  COVID-19 Treatments and Pathogenesis Including Anosmia in K18-hACE2 mice , 2020, Nature.

[18]  P. Dormitzer,et al.  COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses , 2020, Nature.

[19]  S. M. Toor,et al.  T‐cell responses and therapies against SARS‐CoV‐2 infection , 2020, Immunology.

[20]  D. Lauffenburger,et al.  Ad26 vaccine protects against SARS-CoV-2 severe clinical disease in hamsters , 2020, Nature medicine.

[21]  George Oprinca,et al.  Postmortem examination of three SARS-CoV-2-positive autopsies including histopathologic and immunohistochemical analysis , 2020, International Journal of Legal Medicine.

[22]  J. Bloom,et al.  Neutralizing Antibodies Correlate with Protection from SARS-CoV-2 in Humans during a Fishery Vessel Outbreak with a High Attack Rate , 2020, Journal of Clinical Microbiology.

[23]  Shamus P. Keeler,et al.  SARS-CoV-2 infection of hACE2 transgenic mice causes severe lung inflammation and impaired function , 2020, Nature Immunology.

[24]  R. Olsen,et al.  Treatment of Coronavirus Disease 2019 Patients with Convalescent Plasma Reveals a Signal of Significantly Decreased Mortality , 2020, The American Journal of Pathology.

[25]  A. Bernardi,et al.  DC/L-SIGN recognition of spike glycoprotein promotes SARS-CoV-2 trans-infection and can be inhibited by a glycomimetic antagonist , 2020, bioRxiv.

[26]  V. Munster,et al.  ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques , 2020, Nature.

[27]  Zeyu Chen,et al.  T cell responses in patients with COVID-19 , 2020, Nature Reviews Immunology.

[28]  Rebecca J. Loomis,et al.  Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates , 2020, The New England journal of medicine.

[29]  D. Lauffenburger,et al.  Single-Shot Ad26 Vaccine Protects Against SARS-CoV-2 in Rhesus Macaques , 2020, Nature.

[30]  Ying Li,et al.  Antibody responses against SARS‐CoV‐2 in COVID‐19 patients , 2020, Journal of medical virology.

[31]  W. Petri,et al.  Evaluation of K18-hACE2 Mice as a Model of SARS-CoV-2 Infection , 2020, bioRxiv.

[32]  J. Segalés,et al.  Cross-neutralization activity against SARS-CoV-2 is present in currently available intravenous immunoglobulins , 2020, bioRxiv.

[33]  T. Zhao,et al.  A Mouse Model of SARS-CoV-2 Infection and Pathogenesis , 2020, Cell Host & Microbe.

[34]  A. Manenti,et al.  Evaluation of SARS‐CoV‐2 neutralizing antibodies using a CPE‐based colorimetric live virus micro‐neutralization assay in human serum samples , 2020, Journal of medical virology.

[35]  D. Brodie,et al.  Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study , 2020, medRxiv.

[36]  T. Hirano,et al.  COVID-19: A New Virus, but a Familiar Receptor and Cytokine Release Syndrome , 2020, Immunity.

[37]  N. Vaninov.  In the eye of the COVID-19 cytokine storm , 2020, Nature Reviews Immunology.

[38]  P. Zhou,et al.  Histopathologic Changes and SARS–CoV-2 Immunostaining in the Lung of a Patient With COVID-19 , 2020, Annals of Internal Medicine.

[39]  P. Mehta,et al.  COVID-19: consider cytokine storm syndromes and immunosuppression , 2020, The Lancet.

[40]  J. Xiang,et al.  Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study , 2020, The Lancet.

[41]  C. Sorzano,et al.  Deletion of Vaccinia Virus A40R Gene Improves the Immunogenicity of the HIV-1 Vaccine Candidate MVA-B , 2020, Vaccines.

[42]  Y. Hu,et al.  Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China , 2020, The Lancet.

[43]  Victor M Corman,et al.  Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR , 2020, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[44]  C. Sorzano,et al.  Potent Anti-hepatitis C Virus (HCV) T Cell Immune Responses Induced in Mice Vaccinated with DNA-Launched RNA Replicons and Modified Vaccinia Virus Ankara-HCV , 2019, Journal of Virology.

[45]  J. Saiz,et al.  A Vaccine Based on a Modified Vaccinia Virus Ankara Vector Expressing Zika Virus Structural Proteins Controls Zika Virus Replication in Mice , 2018, Scientific Reports.

[46]  C. Muñoz-Fontela,et al.  Distinct Immunogenicity and Efficacy of Poxvirus-Based Vaccine Candidates against Ebola Virus Expressing GP and VP40 Proteins , 2018, Journal of Virology.

[47]  A. Brun,et al.  Efficacy of different DNA and MVA prime-boost vaccination regimens against a Rift Valley fever virus (RVFV) challenge in sheep 12 weeks following vaccination , 2018, Veterinary Research.

[48]  G. Sutter,et al.  Modified Vaccinia Virus Ankara , 2016, Advances in Virus Research.

[49]  C. Sorzano,et al.  A Novel Poxvirus-Based Vaccine, MVA-CHIKV, Is Highly Immunogenic and Protects Mice against Chikungunya Infection , 2014, Journal of Virology.

[50]  M. Esteban,et al.  Clinical applications of attenuated MVA poxvirus strain , 2013, Expert review of vaccines.

[51]  C. Sorzano,et al.  Immunogenic Profiling in Mice of a HIV/AIDS Vaccine Candidate (MVA-B) Expressing Four HIV-1 Antigens and Potentiation by Specific Gene Deletions , 2010, PloS one.

[52]  B. Bartosch,et al.  Infectious Hepatitis C Virus Pseudo-particles Containing Functional E1–E2 Envelope Protein Complexes , 2003, The Journal of experimental medicine.

[53]  P. Palese,et al.  Priming with recombinant influenza virus followed by administration of recombinant vaccinia virus induces CD8+ T-cell-mediated protective immunity against malaria. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[54]  H. Stickl,et al.  [The smallpox vaccination strain MVA: marker, genetic structure, experience gained with the parenteral vaccination and behavior in organisms with a debilitated defence mechanism (author's transl)]. , 1978, Zentralblatt fur Bakteriologie, Parasitenkunde, Infektionskrankheiten und Hygiene. Erste Abteilung Originale. Reihe B: Hygiene, Betriebshygiene, praventive Medizin.

[55]  Dennis Andersson,et al.  A retrospective cohort study , 2018 .

[56]  V. Preedy,et al.  Prospective Cohort Study , 2010 .